Search
Search Results
-
Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy
Purpose of ReviewTyrosine kinase inhibitors (TKI) and monoclonal antibodies (mAbs) that target the epidermal growth factor receptor (EGFR) have...
-
The Anticancer Effect of Metformin Combined with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients with or Without Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
IntroductionDespite the growing evidence for the anticancer effect of metformin or its combination with epidermal growth factor receptor tyrosine...
-
EGF-like growth factors upregulate pentraxin 3 expression in human granulosa-lutein cells
The epidermal growth factor (EGF)-like factors, comprising amphiregulin (AREG), betacellulin (BTC), and epiregulin (EREG), play a critical role in...
-
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation...
-
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Gastric cancer is one of the most common malignancy worldwide. In unresectable or metastatic disease, the prognosis is poor and in generally less...
-
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
BackgroundEndocrine resistant metastatic disease develops in ~ 20–25% of hormone-receptor-positive (HR+) breast cancer (BC) patients despite...
-
Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment
BackgroundReceptor tyrosine kinases (RTKs) are single-pass transmembrane proteins that play significant roles in regulating cellular processes,...
-
Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials
Erlotinib (ELB) is a tyrosine kinase inhibitor that targets the activity of Epidermal Growth Factor Receptor (EGFR) protein found in both healthy and...
-
The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review
Breast cancer (BC) is the most common malignancy in women and one of the leading causes of cancer mortality, despite significant treatment...
-
Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
With the development of molecular biology and histology techniques, targeted therapy for non-small cell lung cancer (NSCLC) has emerged, which is...
-
Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
The discovery of human epidermal growth factor receptor 2 (HER2) overexpression in 15–20% of gastric adenocarcinomas has been a key advance in the...
-
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
BackgroundThis prospective study aims to investigate the efficacy and safety of pyrotinib (P) combined with 4 cycles of epirubicin and...
-
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2...
-
A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma
Afatinib is a second-generation, oral, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). One of the most common adverse effects...
-
The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies
Heparin-binding growth factor (HB-EGF) is a member of the epidermal growth factor (EGF) ligand family which has a crucial role in women’s health....
-
The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction
Therapies that target specific tumor drivers or immune checkpoints are increasingly explored for esophageal cancer patients. This review addresses...
-
A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study
BackgroundEpidermal growth factor receptor (EGFR)- and human epidermal growth factor receptor (HER)2-targeted therapies are approved for the...
-
Betacellulin regulates gap junction intercellular communication by inducing the phosphorylation of connexin 43 in human granulosa-lutein cells
BackgroundThe gap junction protein, connexin 43 (Cx43) is highly expressed in human granulosa-lutein (hGL) cells. The phosphorylation of certain...
-
Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments
Purpose of ReviewAlthough mortality rates have declined significantly in recent years, breast cancer remains the second most common cause of cancer...
-
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer
BackgroundNeuregulin-1 (NRG1) is implicated in both cancer and neurologic diseases such as amyotrophic lateral sclerosis (ALS); however, to date,...
